MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.bmcl.2026.130682

Медицинская библиотека · Bioorganic & medicinal chemistry letters · 2026

Synthesis and preclinical evaluation of 89Zr-DFO-atezolizumab for immuno-PET imaging in colorectal cancer.

Hao Siqi, Jiang Yang, Chen Qian, Zhang Qian, Zhang Yan, Sriwongta Soontaree, Vajragupta Opa, Rojsitthisak Pornchai, Yang Zhi, Zhu Hua

СтатьяПеревод в очереди

Аннотация

The immune checkpoint programmed ligand 1 (PD-L1) is expressed in various solid tumors and is associated with immunotherapy prognosis. Dynamic assessment of PDL1 expression levels helps identify patients who may benefit from immunotherapy. Atezolizumab is a monoclonal antibody that targets PD-L1 and is used in the treatment of various hematologic malignancies and solid tumors. However, research on colon cancer is lacking. Approximately 85% of colorectal cancer (CRC) patients have the MSS/pMMR (Microsatellite Stable/proficient Mismatch Repair) subtype, which lacks ideal biomarkers for precise and dynamic screening of potential immune-responsive subpopulations and for predicting combination therapy strategies. Currently, the assessment of PD-L1 is limited to biopsy samples. Molecular immuno-PET imaging can provide an effective solution for guiding clinical immunotherapy selection. This study describes the development of 89Zr-DFO-atezolizumab, a PD-L1-targeted immuno-imaging agent, and its evaluation in terms of in vitro and in vivo specificity as well as pharmacokinetics. Tumor uptake and heterogeneity were quantified in mouse models via immuno-PET imaging. PET/CT scans using 89Zr-DFO-atezolizumab revealed a significant difference in tumor uptake between the MC38hPD-L1 model and the MC38 model, and cold anti-atezolizumab effectively blocked this uptake. The preliminary dosimetry study indicated that the organs receiving higher doses are the spleen and the liver. Preclinical PET/CT imaging with 89Zr-DFO-atezolizumab reveals its potential for the non-invasive detection of PD-L1-positive CRC tumors, which holds potential significance for understanding tumor heterogeneity and monitoring early PD-L1 expression changes induced by therapy.

Для цитирования: Hao Siqi, Jiang Yang, Chen Qian, Zhang Qian, Zhang Yan, Sriwongta Soontaree, Vajragupta Opa, Rojsitthisak Pornchai, Yang Zhi, Zhu Hua. Synthesis and preclinical evaluation of 89Zr-DFO-atezolizumab for immuno-PET imaging in colorectal cancer.. Bioorganic & medicinal chemistry letters. 2026. DOI: 10.1016/j.bmcl.2026.130682.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.